Spruce Biosciences (SPRB) Cash from Financing Activities (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Cash from Financing Activities of $13.9 million for Q1 2026, up 3485.89% year-over-year from $388076.8 in Q1 2025, and down 68.86% quarter-over-quarter from $44.7 million in Q4 2025.
Spruce Biosciences (SPRB) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Cash from Financing Activities for 8 consecutive years, with $13.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 3485.89% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $57.8 million (up 3300.89% YoY), while the FY2025 annual figure was $43.5 million, up 2780.7% from the prior year.
- Cash from Financing Activities declined to $13.9 million in Q1 2026 per SPRB's latest filing, from $44.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $50.5 million in Q1 2023 and bottomed at -$625000.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $6.2 million across 5 years, with a median of -$365000.0 in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 57519.32% in 2023 and fell as far as 1633.33% in 2023.
- Spruce Biosciences' Cash from Financing Activities stood at $36000.0 in 2022, then tumbled by 1633.33% to -$552000.0 in 2023, then slipped by 13.22% to -$625000.0 in 2024, then surged by 7251.04% to $44.7 million in 2025, then plunged by 68.86% to $13.9 million in 2026.
- Business Quant data shows SPRB's Cash from Financing Activities at $13.9 million in Q1 2026, $44.7 million in Q4 2025, and -$402000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 64.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.47 Mn |
| Jun 30, 2026 | 64.47 Mn |
| Mar 31, 2026 | 13.92 Mn |
| Mar 31, 2026 | 13.92 Mn |
| Dec 31, 2025 | 44.69 Mn |
| Dec 31, 2025 | 44.69 Mn |
| Sep 30, 2025 | -402,000.00 |
| Sep 30, 2025 | -402,000.00 |
| Jun 30, 2025 | -400,000.00 |
| Jun 30, 2025 | -400,000.00 |
| Mar 31, 2025 | -411,000.00 |
| Mar 31, 2025 | -411,000.00 |
| Dec 31, 2024 | -625,000.00 |
| Dec 31, 2024 | -625,000.00 |
| Sep 30, 2024 | -405,000.00 |
| Sep 30, 2024 | -405,000.00 |
| Jun 30, 2024 | -365,000.00 |
| Jun 30, 2024 | -365,000.00 |
| Mar 31, 2024 | -227,000.00 |
| Mar 31, 2024 | -227,000.00 |